Referenced in: none

Automatically associated channels: TRP , TRPV , TRPV1

Title: TRPV1-antagonist AMG9810 promotes mouse skin tumorigenesis through EGFR/Akt signaling.

Authors: Shengqing Li, Ann M Bode, Feng Zhu, Kangdong Liu, Jishuai Zhang, Myoung Ok Kim, Kanamata Reddy, Tatyana Zykova, Wei-Ya Ma, Andria L Carper, Alyssa K Langfald, Zigang Dong

Journal, date & volume: Carcinogenesis, 2011 May , 32, 779-85

PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/21349818

Abstract
In addition to capsaicin, a transient receptor potential channel vanilloid subfamily 1 (TRPV1) agonist, two kinds of antagonists against this receptor are used as therapeutic drugs for pain relief. Indeed, a number of small molecule TRPV1 antagonists are currently undergoing Phase I/II clinical trials to determine their effect on relieving chronic inflammatory pain and migraine headache pain. However, we previously reported that the absence of TRPV1 in mice results in a striking increase in skin carcinogenesis, suggesting that chronic blockade of TRPV1 might increase the risk of tumor development. In this study, we found that a typical TRPV1 antagonist, AMG9810, promotes mouse skin tumor development. The topical application of AMG9810 resulted in a significant increase in the expression level of the epidermal growth factor receptor (EGFR) and its downstream Akt/mammalian target of rapamycin (mTOR)-signaling pathway. This increase was not only observed in AMG9810-treated tumor tissue but was also found in skin tissue treated with AMG9810. In telomerase-immortalized primary human keratinocytes, AMG9810 promoted proliferation that was mediated through the EGFR/Akt/mTOR-signaling pathway. In summary, our data suggest that the TRPV1 antagonist, AMG9810, promotes mouse skin tumorigenesis mediated through EGFR/Akt/mTOR signaling. Thus, the application of this compound for pain relief might increase the risk of skin cancer.